β-catenin is a Potential Prognostic Biomarker in Uterine Sarcoma
Technology in Cancer Research & Treatment · 2025
DOI: 10.1177/15330338251345208 ↗Kurz gefasst
Fachartikel in der Zeitschrift Technology in Cancer Research & Treatment, 2025. Verfasst von Ying Cai und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, P. R. China. Hauptthemen laut MEDLINE: beta Catenin, Biomarkers, Tumor, Uterine Neoplasms, Sarcoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Collaborative Innovation Center of Chinese Ministry of Education, Excellent Young Talent Cultivation Project of Zunyi City, Chunhui program of the Chinese Ministry of Education.
Abstract (Originalsprache)
Introduction
Uterine sarcoma (US) is an extremely rare and aggressive gynecologic malignancy with a poor overall survival (OS). The efficient prognostic biomarker is currently lacking.
Methods
Utilizing a Sweden microarray dataset from the Gene Expression Omnibus (GEO) (GSE119043, n = 50) and a clinical cohort (n = 31) retrospectively collected from Suining Central Hospital, we analyzed β-catenin expression profiles and corresponding clinicopathological characteristics. Immunohistochemistry (IHC) was used to assess β-catenin expression level. Survival analysis was used to assess the relationship between β-catenin expression and prognosis. Gene set enrichment analysis (GSEA) was performed to characterize the specific pathways involved in β-catenin expression.
Results
Immunohistochemistry indicated that β-catenin expression was significantly upregulated in US group compared to both the normal uterine smooth muscle (UNSM) and uterine leiomyoma (ULM) groups ( P < .01). IHC also exhibited a significant difference in β-catenin expression levels in four pathological subtypes. Leiomyosarcoma (LMS) and high-grade endometrial stromal sarcoma (HG-ESS) suggested higher levels of β-catenin expression compared with adenosarcoma (AS) or low-grade endometrial stromal sarcoma (LG-ESS), but no statistically significant difference was found in box plot ( P > .05). GSEA indicated that transcriptional dysregulation in cancer, Wnt, AMPK, MAPK, PI3K, p53, Ras, and TNF signaling pathway were positively enriched in β-catenin high-expression group. Though survival analysis showed that β-catenin expression level was not associated with survival, low-β-catenin expression group showed a longer median OS compared to high expression group (56.17 months VS 9.60 months) in Sweden microarray dataset. Similar results were also observed for progression-free survival (PFS) in clinical cohort (not reached VS 45.97 months in high-expression group). Tumor type, lymphadenectomy, family history of malignancy and tumor recurrence remained significant predictors of OS, while only tumor type, stage and tumor recurrence had prognostic significance for PFS. Age, tumor size, menopausal status, CA125, adjuvant chemotherapy, and adjuvant radiotherapy, were not associated with survival ( P > .05). Conclusion β-catenin was highly expressed in uterine sarcoma and may be promising as a novel potential biomarker for diagnosis and prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, P. R. China.
- Department of Pathology, Suining Central Hospital, Suining, P. R. China.
- Department of Orthodontics, Affiliated Stomatological Hospital of Zunyi Medical University, Zunyi, P. R. China.
- Translational Radiobiology, Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
- Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
- FAU Profile Center Immunomedicine (FAU I-MED), Friedrich-Alexander- Universität Erlangen-Nürnberg, Erlangen, Germany.
ORCID-Profile: Ying Cai, Yunjia Wang, Min-Jun Chen, Chi Zhang, Jian-Guo Zhou
Förderung
- Collaborative Innovation Center of Chinese Ministry of Education
- Excellent Young Talent Cultivation Project of Zunyi City
- Chunhui program of the Chinese Ministry of Education
- Future Science and Technology Elite Talent Cultivation Project of Zunyi Medical University
- Natural Science Foundation of Guizhou Province
- China Lung Cancer Immunotherapy Research Project
- National Natural Science Foundation of China
- Youth Talent Project of Guizhou Provincial Department of Education
Zitieren
APA
Cai, Y., Wang, Y., Yang, L., Huang, Y., Chen, M. J., Zhang, C., Jin, S. H., Frey, B., Gaipl, U. S., Ma, H., & Zhou, J. G. (2025). β-catenin is a Potential Prognostic Biomarker in Uterine Sarcoma. Technology in Cancer Research & Treatment. https://doi.org/10.1177/15330338251345208
Vancouver
Cai Y, Wang Y, Yang L, Huang Y, Chen MJ, Zhang C, et al. β-catenin is a Potential Prognostic Biomarker in Uterine Sarcoma. Technology in Cancer Research & Treatment. 2025. doi:10.1177/15330338251345208
BibTeX
@article{Cai2025,
author = {Cai, Ying and Wang, Yunjia and Yang, Ling and Huang, Yue and Chen, Min-Jun and Zhang, Chi and Jin, Su-Han and Frey, Benjamin and Gaipl, Udo S and Ma, Hu and Zhou, Jian-Guo},
title = {β-catenin is a Potential Prognostic Biomarker in Uterine Sarcoma},
journal = {Technology in Cancer Research & Treatment},
year = {2025},
doi = {10.1177/15330338251345208}
}
EUVIMED